fda status of bpc 157 2024 When will the reclassify BPC-157 to Category 1? Odds & Predictions BPC-157 Legal Status: FDA Regulations

Neuroprotective effects of PARP inhibitors in Drosophila models of Alzheimers disease

[DOI] [PubMed] [Google Scholar] 101.Hedberg EL, Kroese-Deutman HC, Shih CK, Crowther RS, Carney DH, Mikos AG, et al

Archived (PDF) from the original on 2008-02-21

Lancet 389 (10070), 736747

The methodology is explicitly described as descriptive rather than causal: 1,778 patients enrolled, 177 respondents, external comparator drawn from 16 tirzepatide publications, internal confidence intervals shown with Wilson methods, and a warning that the comparison does not establish comparative efficacy or safety

Given the ability of MK-677 to extend these critical sleep stages in healthy subjects, further investigation of the compound for its sleep-related benefits is warranted